Literature DB >> 15629308

Recurrent Staphylococcus aureus chalazia in hyperimmunoglobulinemia E (Job's) syndrome.

John J Destafeno1, Sylvia R Kodsi, Jonathan D Primack.   

Abstract

PURPOSE: To report a case of recurrent Staphylococcus aureus chalazia in a patient with hyperimmunoglobulinemia E syndrome (Job's Syndrome).
DESIGN: Case report.
METHODS: Three separate surgical incisions and curettages of multiple, recurrent chalazia of the right upper eyelid were performed over a course of 3 months. Cultures and pathologic specimens were obtained. Postoperative treatment consisted of oral erythromycin and amoxicillin/clavulonate, topical tobramycin/dexamethasone ointment, and warm compresses.
RESULTS: Pathology of the tarsus confirmed the diagnosis of multiple chalazia. Cultures of the chalazia contents were positive for Staphylococcus aureus. No further recurrence was observed following the third surgical procedure over a 3-month follow-up period.
CONCLUSION: Characteristic Staphylococcus aureus skin infections in immunodeficient patients with hyperimmunoglobulinemia E syndrome can involve the eyelids and may be recurrent despite appropriate medical and surgical therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15629308     DOI: 10.1016/j.ajo.2004.06.034

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Recurrent giant chalazia in hyperimmunoglobulin E (Job's) syndrome.

Authors:  Pierpaolo Patteri; Alain Serru; Maria Letizia Chessa; Michele Loi; Antonio Pinna
Journal:  Int Ophthalmol       Date:  2008-06-05       Impact factor: 2.031

Review 2.  STAT3 Hyper-IgE Syndrome-an Update and Unanswered Questions.

Authors:  Christo Tsilifis; Alexandra F Freeman; Andrew R Gennery
Journal:  J Clin Immunol       Date:  2021-05-01       Impact factor: 8.317

3.  Ophthalmic complications including retinal detachment in hyperimmunoglobulinemia E (Job's) syndrome: Case report and review of literature.

Authors:  Vipul Arora; Usha R Kim; Hadi M Khazei; Shivayogi Kusagur
Journal:  Indian J Ophthalmol       Date:  2009 Sep-Oct       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.